• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

    1/27/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email

    $20 million additional funding is planned for 2026 to support programs and impact investments that increase access to Cardiovascular, Surgery and Vision care

    Partnerships with global and local organizations, alongside continued product donations, will equip the health workforce with tools, trainings and support

    Builds on longstanding efforts by Johnson & Johnson and the J&J Foundation to champion and support health workers

    Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communities in 2026.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127404738/en/

    These new funds are part of J&J CareCommunity, a social impact platform that focuses the work of Johnson & Johnson and the J&J Foundation to champion health workers and advance access to quality care. Alongside partners like Lions Clubs International Foundation, Operation Smile and the American Heart Association, J&J CareCommunity is helping improve the lives of health workers and patients alike.

    "With these efforts, we're accelerating the work of J&J CareCommunity, partnering with global and local organizations to deliver new tools, training and sustained support that frontline care teams need to expand access to specialized care," said Tim Schmid, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson. "As a leader in medical technology, we know that delivering specialized care doesn't just help people. It also fuels healthier communities, stronger economies and lasting change."

    Gaps in access to specialized care are caused in part by shortages of skilled surgical and health workers and a lack of technologies and infrastructure, which strain providers and health systems in under-resourced communities. Johnson & Johnson is helping close these gaps by providing medical tools and technologies to equip health workers to deliver specialized care, which includes restoring circulation, healing wounds, helping people see clearly again and other life-changing care.

    The Company and the J&J Foundation are also working with partners to build programs that train and support health workers involved in this care. Each year, these efforts reach over 300,000 healthcare professionals, to enable the uptake of tools and technologies that make safe surgical care possible.

    "Safe surgery gives children the chance to breathe freely, speak clearly, and move through life with confidence," said Kristie Magee Porcaro, Chief Strategy Officer, Operation Smile. "Yet too many still lack access to these essential procedures. By strengthening health systems and equipping local health workers and leaders, we help bring life-changing care closer to home, fostering resilient communities and creating a future full of possibilities."

    Scaling Impact through Global Partnerships

    Through J&J CareCommunity, the Company and the J&J Foundation are working with several global partners to reach more people, now and in the future, including:

    • American Heart Association: Johnson & Johnson, in collaboration with the American Heart Association, is expanding access to CPR trainings for employees and communities, including a new hands-only CPR training kiosk at the Museum of Science in Boston, an innovative, interactive way for everyday people to practice lifesaving skills.
    • Global Surgery Foundation: Johnson & Johnson, with support from the J&J Foundation, is collaborating with the Global Surgery Foundation to support surgical teams as a founding partner of the UN Global Surgery Learning Hub (SURGhub), and through a $1 million commitment to SURGfund to scale surgical systems in low- and middle-income countries.
    • International Agency for the Prevention of Blindness (IAPB): Johnson & Johnson and the J&J Foundation are working with IAPB to elevate eye health on national agendas and strengthen health systems to accelerate progress toward the shared goal of ending preventable blindness by 2030.
    • MAP (Medicine for All People): Through a longstanding collaboration with MAP, Johnson & Johnson is donating products, including sutures, intraocular lenses, bladder sounds, fistula scissors and catheter organizers, to equip health workers with the tools to deliver safe surgery in communities globally.
    • Operation Smile: For over 35 years, Johnson & Johnson and the J&J Foundation has partnered with Operation Smile to expand access to safe surgery. What began with providing sutures has grown into a partnership that brings care and new smiles within reach, while equipping nurses with leadership and skills trainings, creating lasting change in local communities.
    • SEE International: Johnson & Johnson and the J&J Foundation are supporting SEE International to help medical teams and volunteers bring free sight-restoring surgeries to people living with cataracts.
    • Sight For Kids: In 2002, we teamed up with Lions Clubs International Foundation (LCIF) to launch Sight For Kids (SFK), a program that connects children in low-income schools with comprehensive eye health screenings and care at no cost. SFK, with support from the J&J Foundation, has reached more than 55 million students around the world. Now the program is training community health workers to reach more communities.

    Johnson & Johnson's Commitment to the Global Health Workforce

    As healthcare advances, we believe in supporting those who shape it – healthcare professionals. J&J CareCommunity is a global social impact platform from Johnson & Johnson to advance access to quality care through championing nurses and community health workers. By collaborating with those closest to the challenge, we can connect more people to care. Learn more at https://www.jnj.com/j-j-care-community.

    About Johnson & Johnson

    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

    © Johnson & Johnson and its affiliates 2026. All rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260127404738/en/

    Media contact:

    Lindsey Diaz-MacInnis

    [email protected]

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    11/13/2025$230.00Sector Outperform
    Scotiabank
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    7/23/2025Hold → Buy
    Erste Group
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    More analyst ratings

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CIO Swanson James D. sold $15,109,759 worth of shares (62,080 units at $243.39), exercised 73,140 shares at a strike of $139.50 and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 36% to 25,698 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:32 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief TO and Risk Officer Wengel Kathryn E covered exercise/tax liability with 7,266 shares and converted options into 15,598 shares, increasing direct ownership by 8% to 114,288 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:26 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief HR Officer Mulholland Kristen converted options into 5,006 shares and covered exercise/tax liability with 1,585 shares, increasing direct ownership by 21% to 19,830 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

    More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients  78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement)STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 compa

    2/21/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

    Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of careRARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated. Data were presented during a plenary session at the 2026 Multid

    2/19/26 5:00:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

    Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company's portfolio of transformational medicines Facility will boost Pennsylvania's economy by creating more than 4,000 construction jobs and 500 biomanufacturing jobs, while further strengthening the Company's annual $10 billion economic impact across the state Investment is part of Company's $55 billion U.S. investment by early 2029 and supports plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S. Johnson & Johnson (NYSE:JNJ) (the "Company"), healthcare's leading, most comprehensive innovation powerhouse, today ann

    2/18/26 10:15:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    SEC Filings

    View All

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/13/26 4:24:01 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Johnson & Johnson

    S-3ASR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 5:24:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Johnson & Johnson

    10-K - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 4:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Johnson & Johnson reports Q4 and Full-Year 2025 results

    2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisition of Halda Therapeutics 2025 Full-Year reported sales growth of 6.0% to $94.2 Billion with operational growth of 5.3%* and adjusted operational growth of 4.2%*; 2025 Full-Year earnings per share (EPS) of $11.03 and adjusted EPS of $10.79, both include $(0.10) due to the acquisition of Halda Therapeutics Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for

    1/21/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company's common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely p

    1/2/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care